<DOC>
	<DOCNO>NCT00676234</DOCNO>
	<brief_summary>Pilot study aim assess effect two dos rhu EPO urine NGAL concentration serum cystatin C creatinine level critically ill patient risk ARF .</brief_summary>
	<brief_title>Recombinant Human Erythropoietin Use Intensive Care Unit ( ICU ) Patients : Does Prevent Acute Renal Failure</brief_title>
	<detailed_description>Research plan Open-label randomize trial Twelve month duration trial Setting : Medical Surgical Intensive Care Unit University Hospitals Geneva Start trial : Mid-May 2008 Patients randomly allocate 2 treatment group ( 20 patient per group ) , control group ( 40 patient ) : - Group 1 : control group ( 40 patient ) - Group 2 : 20000 IU rhu Epo ( 20 patient ) administer i.v . route - Group 3 : 40000 IU rhu Epo ( 20 patient ) administer i.v . route 3.2 . Trial design Day 0 Consent form sign Patients randomly allocate control treatment group ( 20000 40000 IU ) Serum Cystatin C determination Serum Creatinine determination Urinary NGAL determination Administration intravenous rhu Epo Day 0 Epo ( control group ) Day 2 At 48 hr rhu EPO injection , sample take - Serum Cystatin C determination - Serum Creatinine determination - Urinary NGAL determination Day 4 At 96 hr rhu EPO injection , sample take - Serum Cystatin C determination - Serum Creatinine determination - Urinary NGAL determination Stopping rule The trial individual subject , part trial entire trial stop : - Day 4 individual subject - enrollment 80 patient Treatment The treatment consist intravenous ( i.v . ) injection recombinant human erythropoietin ( r-hu-EPO ) . The trial medication provide JANSSEN-CILAG AG . The brand name EPREXÂ® epoietinum-alpha sterile buffer solution i.v . s.c. injection . Patient group 1 receive EPO treatment . Patient group 2 receive 20'000 U rhu EPO patient group 3 receive 40'000 U rhu EPO ( i.v . route ) .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Acute Kidney Injury</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients risk acute tubular necrosis ( patient mechanical ventilation , patient sepsis , postoperative state , hemodynamic impairment previous chronic renal failure . Consent form sign Patients malignant hypertension Patients systolic BP &gt; 150 mmHg enrollment Patients Hb level &gt; 120g/L Patients acute coronaropathy Pregnancy Patients urine output &lt; 600 ml/12 h</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>erythropoietin</keyword>
</DOC>